Psoriasis Clinical Trial
Official title:
Psorcast Study: A Smartphone-based Study of Psoriasis and Psoriatic Arthritis
NCT number | NCT05621369 |
Other study ID # | 202110921 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2022 |
Est. completion date | January 31, 2027 |
The purpose of this study is to understand variation in the symptoms of psoriasis and psoriatic arthritis using simple, scalable smartphone-based measurements. This study uses an iPhone app to record these symptoms through questionnaires and sensors.
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | January 31, 2027 |
Est. primary completion date | January 31, 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult age 18 and older who consent to participate in the study - Own a compatible iPhone or iPod Touch device running iOS 12.2 or above - Be able to read and understand an official language of the country of participation Exclusion Criteria: - Age 17 years or younger - Not a resident of the a country where the app is approved for use - Not have a personal (i.e., not shared) iPhone (4s or newer running iOS 8.0 or later) - Not be able to read and understand an official language of the country of participation |
Country | Name | City | State |
---|---|---|---|
United States | Sage Bionetworks | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Sage Bionetworks | Brigham and Women's Hospital, Harvard Medical School (HMS and HSDM), New York University, NYU Langone Health, University of Pennsylvania |
United States,
DE Webster, RH Haberman, LM Perez Chada, M Tummalacherla, A Tediarjo, V Yadav, E Chaibub Neto, W MacDuffie, M DePhillips, E Sieg, S Catron, C Grant, W Francis, M Nguyen, M Yussuff, RL Castillo, D Yan, AL Neimann, SM Reddy, A Ogdie, A Kolivras, MR Kellen, LM Mangravite, SK Sieberts, L Omberg, JF Merola, JU Scher medRxiv 2022.04.13.22273676; doi: https://doi.org/10.1101/2022.04.13.22273676
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Results of participant self-assessment surveys | Results of participant self-assessment surveys will be analyzed using descriptive statistics. These results may also be compared with other intervention results. | Through study completion, an average of 2 years | |
Primary | Body surface area and location from the Psoriasis Draw assessment | The investigators will quantify body surface area and psoriasis area hotspots across the cohort. These results may also be compared with other intervention results. | Through study completion, an average of 2 years | |
Primary | Computer vision features from Psoriasis Area Photo assessment | The investigators apply visual processing and classifier algorithms to analyze the images from the Psoriasis Area Photo assessments. These results may also be compared with other intervention results. | Through study completion, an average of 2 years | |
Primary | Computer vision features from Finger/Toe Photos | The investigators apply visual processing and classifier algorithms to segment nails and joints from hand and foot photos. These results may also be compared with other intervention results. | Through study completion, an average of 2 years | |
Primary | Gyroscope and accelerometer sensor measurements from Digital Jar Open assessment | The investigators examine rotational features from gyroscope and accelerometer sensors. The investigators apply feature selection and classifier algorithms to analyze these data. These results may also be compared with other intervention results. | Through study completion, an average of 2 years | |
Primary | Gyroscope and accelerometer sensor measurements from 30-sec Walk assessment | The investigators examine step-dependent and sequence-dependent features from gyroscope and accelerometer sensors. The investigators apply feature selection and classifier algorithms to analyze these data. These results may also be compared with other intervention results. | Through study completion, an average of 2 years | |
Primary | Quantification and distribution of self-reported painful joints | The investigators will quantify the self-reported painful joints and, in particular, compare to measurements from the 30-sec Walk and Digital Jar Open to identify correlations. These results may also be compared with other intervention results. | Through study completion, an average of 2 years | |
Secondary | App usage data for assessment of participant engagement | App usage data is used to gauge participant engagement throughout the study period. These results may also be compared with other intervention results. | Through study completion, an average of 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |